Journal Mobile Options
Table of Contents
Vol. 62, No. 1, 2004
Issue release date: July 2004
Section title: Review
Horm Res 2004;62:40–48
(DOI:10.1159/000078786)

Hormone Therapy after Endometrial Cancer

Mueck A.O. · Seeger H.
Section of Endocrinology and Menopause, Women’s University Hospital, Tübingen, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 11/6/2003
Accepted: 3/16/2004
Published online: 7/2/2004

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 4

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: http://www.karger.com/HRP

Abstract

Endometrial carcinoma is listed among the absolute contra-indications to hormone therapy. After all the existing opinions so far, hormone therapy after FIGO stage I or II endometrial cancer is still thought of as a possibility, and up to now the continuous combined oestrogen/progestogen replacement therapy would be recommended. However, until today, only observational studies have been put forward. Although no study has established an increased rate of recurrences or mortality, alternatives such as phytopreparations, tibolone, or, in, particular, psychotherapeutic drugs such as venlafaxine should be considered for the relief of climacteric complaints. Progestogen-only therapy also comes particularly into question. Indeed, the wider discussion about the gestagen effects regarding the risks of breast cancer is to be considered. Generally, after hysterectomy, at least for patients with cardiovascular risk factors, the preference today is to use low-dose oestrogen therapy (patches, gels) instead of continuous combined oestrogen/progestogen replacement therapy, and this also is now recommended for patients after endometrial cancer. This is to be noted because of the risk factors for endometrial carcinomas, such as hypertension, obesity, polycystic ovary syndrome, diabetes mellitus, etc. However, each form of hormone therapy should only be exceptionally recommended, and the patients must be informed about the risks that exist and the use of alternatives.


Article / Publication Details

First-Page Preview
Abstract of Review

Received: 11/6/2003
Accepted: 3/16/2004
Published online: 7/2/2004

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 4

ISSN: 1663-2818 (Print)
eISSN: 1663-2826 (Online)

For additional information: http://www.karger.com/HRP


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland – Häufigkeiten und Trends, ed 3. Saarbrücken 2002.
  2. Sturdee DW: Is ‘HRT’ the correct terminology. J Br Menopause Soc 2003;9:53.
  3. American College of Obstetricians and Gynecologists Committee Opinion: Committee on Gynecologic Practice: Estrogen Replacement Therapy and Endometrial Cancer, No.126, 1993.
  4. Creasman WT: HRT and women who have had breast or endometrial cancer. J Epidemiol Biostat 1999;4:217–225.
  5. Mueck AO, Wallwiener D: Hormonsubstitution nach Brustkrebs. Med Welt 2003;54:51–56.
  6. American Cancer Society: Cancer Facts and Figures. Atlanta, American Cancer Society, 2002.
  7. Oehler MK, Brand A, Wain GV: Molecular genetics and endometrial cancer. J Br Menopause Soc 2003;9:27–31.

    External Resources

  8. Kenemans P: Postmenopausal sex hormones and cancer of the endometrium and breast. J Br Menopause Soc 2000;6(Supp.3):4–9.
  9. Römer T, Mueck AO: Endometrium und Hormonsubstitution. Stuttgart, Thieme, 1998, pp 47–54.
  10. Mueck AO, Seeger H, Wallwiener D: Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. Maturitas 2002;43:87–93.
  11. Mueck AO, Seeger H: Smoking, estradiol metabolism and hormone replacement therapy. Arzneimittelforschung 2003;53:1–11.
  12. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–1037.
  13. Bjarnason K, Cerin A, Lindgren R, Weber T: Adverse endometrial effects during long cycle hormone replacement therapy. Scandinavian Long Cycle Study Group. Maturitas 1999;32:161–170.
  14. Erkkola R, Kumento U, Lehmuskoski S, Mattila L, Mustonen M: No increased risk of endometrial hyperplasia with fixed long-cycle hormone replacement therapy after two years. J Br Menopause Soc 2002;8:155–156.
  15. Rabe T, Mueck AO, Deuringer FU, Runnebaum B: Spacing out of progestin – efficacy, tolerability and compliance of two regimens for hormonal replacement in the late postmenopause. Gynecol Endocrinol 1997;11:383–392.
  16. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I: Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131–1137.
  17. Hill DA, Weiss NS, Beresford SA, Voigt LF, Daling JR, Stanford JL, Self S: Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183:1456–1461.
  18. Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, Nielsen B, Anderson MC, Bragg AJ: The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynaecol 2000;107:1392–1400.
  19. Grady D, Gebretsadik T, Kerlikowski K, Ernster V, Petitti D: Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304–315.
  20. Bertone E, Weiderpass E: Low dose oestrogens and endometrial cancer. J Br Menopause Soc 2000;6:89–92.
  21. Creasman WT, Henderson D, Hinshaw W, Clarke-Pearson DL: Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326–330.
  22. Lee RB, Burke TW, Park RC: Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncology 1990;36:189–191.
  23. Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML: Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195–1200.
  24. Suriano KA, McHale M, McLaren CE, Li KF, Re A, DiSaja PJ: Estrogen replacement therapy in endometrial cancer patients: A matched control study. Obstet Gynecol 2001;97:955–960.
  25. Lauritzen C: Östrogensubstitution in der Postmenopause vor und nach behandeltem Genital- und Mammakarzinom; in Lauritzen C (ed): Menopause: Hormonsubstitution heute. Basel, Aesopus Verlag, 1993, pp. 76–80.
  26. Bryant GW: Administration of estrogens in patients with a previous diagnosis of endometrial adenocarcinoma. South Med J 1990;83:725–726.
  27. Baker DP: Estrogen-replacement therapy in patients with previous endometrial carcinoma. Compr Ther 1990;16:28–35.
  28. Carr JA, Schoon PA, Look KY: An atypical recurrence of endometrial carcinoma following estrogen replacement therapy. Gynecol Oncol 1996;60:498–499.
  29. Bullock JL, Massey FM, Gambrell RD Jr: Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol 1975;46:165–168.
  30. Morrison JC, Martin DC, Blair RA, Anderson GD, Kincheloe BW, Bates GW, Hendrix JW, Rivlin ME, Forman EK, Propst MG, Needham R: The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980;138:99–104.
  31. Albrecht BH, Schiff I, Tulchinsky D, Ryan KJ: Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes. Am J Obstet Gynecol 1981;139:631–635.
  32. Schiff I, Tulchinsky D, Cramer D, Ryan KJ: Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443–1445.
  33. Loprinzi CL, Michalek JC, Quella SK, O’Fallon JR, Hatfield AK, Nelimark RA, Dose AM, Fischer T, Johnson C, Klatt NE, et al: Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994;331:347–352.
  34. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T: Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998;82:1784–1788.
  35. Farish E, Barnes JF, O’Donoghue F, Fletcher CD, Ekevall K, Hart DM: The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric 2000;3:125–134.
  36. Marsden J: Hormone replacement therapy and breast cancer. Lancet Oncol 2002;3:303–311.
  37. Seeger H, Wallwiener D, Mueck AO: Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells. J Br Menopause Soc 2003;9:36–38.
  38. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613.
  39. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
  40. Mikkola TS, Clarkson TB: Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002;53:605–619.

    External Resources

  41. Mueck AO, Seeger H, Haasis R, Gohlke-Bärwolf C, Schieber M, Schuchert A, Meinertz T: Effect of oral vs. transdermal estradiol on cGMP during exercise in women with coronary artery disease – randomized, double-blind, placebo-controlled crossover study. Circulation 1999;100(18 Suppl):1386.
  42. Hillard T: Serving without stimulation. J Br Menopause Soc 2000;6(Suppl 2):11–13.
  43. Mueck AO, Seeger H: Statins and menopausal health. J Br Menopause Soc 2002;8:141–146.
  44. Kloosterboer HJ, Sands R: Intracinology: The secret of the tissue specificity of tibolone. J Br Menopause Soc 2000;6(Suppl 2):23–27.
  45. Deutsche Gesellschaft für Senologie: Konsensus: Hormonsubstitution nach Mammakarzinom. Geburtshilfe Frauenheilkd 2002;62:1113–1115.
  46. Mueck AO, Stoll KD: Opipramol bei menopausalem Syndrom als Alternative bei Kontraindikationen gegen Hormonsubstitution; in Müller WE, Möller HJ (eds): Opipramol, Sigmaligand und stimmungsaufhellendes Anxiolytikum. Neu-Isenburg, LinguaMed Verlag, 2001, pp 137–146.
  47. Guttuso T Jr, Kurlan R, McDermott MP, Kieburtz K: Gabapentin’s effects on hot flashes in postmenopausal women: A randomized controlled trial. Obstet Gynecol 2003;101:337–345.

    External Resources

  48. Albertazzi P: Management of hot flushes without oestrogen. J Br Menopause Soc 2002;8:147–151.
  49. Johnson EB, Muto MG, Yanushpolsky EH, Mutter GL: Phytoestrogen supplementation and endometrial cancer. Obstet Gynecol 2001;98(5 Pt 2):947–950.
  50. North American Menopause Society: The role of isoflavones in menopausal health: Consensus opinion of the North American Menopause Society. Menopause 2000;7:215–229.
  51. Glazier MG, Bowman MA: A review of the evidence for the use of phytoestrogens as a replacement for traditional estrogen replacement therapy. Arch Intern Med 2001;161:1161- 1172.
  52. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM: Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110–1116.
  53. Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C: Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253–260.
  54. Beresford SA, Weiss NS, Voigt LF, McKnight B: Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458–461.